CHEST Clinical Trials Opportunities

Treatments for COPD may still leave you looking for relief from wheezing, coughing, and shortness of breath. That’s why Sanofi and Regeneron are researching if an investigational medicine plus certain controller therapies could potentially lessen COPD symptoms and improve breathing and overall well-being in former smokers who are between 40 and 85 years old with moderate to severe COPD. This global, multicenter, phase 3 clinical trial (AERIFY 2) is a randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate to severe COPD.

A number of clinical trial sites are available and recruiting patients across the United States. For additional information, or to learn if you might be eligible, please visit Sanofi Studies or ClinicalTrials.gov.

Treatments for COPD may still leave you looking for relief from wheezing, coughing, and shortness of breath. That’s why Sanofi and Regeneron are researching the mechanism of action of an investigational medicine in former and current smokers who are between 40 and 70 years old with COPD.

This global, multicenter, phase 2a clinical trial (AERIFY 3) is an exploratory, two-part, 12-week study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) and its impact on airway inflammation. This study consists of participants who have been on a standard-of-care mono (long-acting β2-agonist [LABA] or long-acting muscarinic antagonist [LAMA]), double (inhaled corticosteroid [ICS] + LABA, LABA + LAMA, or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to screening (Visit 1) and during the screening period. Participants will stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD.

A number of clinical trial sites are available and recruiting patients across the United States. For additional information, or to learn if you might be eligible, please visit Sanofi Studies or ClinicalTrials.gov.

Sanofi and Regeneron are studying the long-term effect of dupilumab on the prevention of lung function decline in adult patients with uncontrolled moderate to severe asthma. This phase 3b/4 study (ATLAS) is an interventional, randomized, parallel group, treatment, double-blind, two-arm study to assess the effect of dupilumab compared with standard-of-care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.

The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double-blinded treatment period. There will be a post-treatment follow-up period up to 12 weeks.

A number of clinical trial sites are available and recruiting patients across the United States. For additional information, or to learn if you might be eligible, please visit Sanofi Studies or ClinicalTrials.gov.

Boehringer Ingelheim is conducting a phase 3 clinical trial in adults 18 years of age or older who are diagnosed with interstitial lung disease (ILD) with progressive pulmonary fibrosis. If they already take nintedanib for their ILD, they can continue treatment throughout the study. The FIBRONEER™-ILD study aims to evaluate the safety and effectiveness of an oral investigational drug, BI 1015550 (a phosphodiesterase 4B inhibitor), when compared with a placebo. Approximately 1,040 participants will take part in the ILD study, which involves around 400 study centers worldwide. This trial is currently enrolling participants. Participants who complete FIBRONEER-ILD will be offered the chance to participate in the long-term open-label extension study, FIBRONEER-ON. For more information on the study eligibility criteria and trial sites, please visit ClinicalTrials.gov (NCT05321082). https://classic.clinicaltrials.gov/ct2/show/NCT05321082

Contact information: Boehringer Ingelheim, +1 (800) 243-0127 or clintriage.rdg@boehringer-ingelheim.com

Boehringer Ingelheim is recruiting patients who have pulmonary fibrosis and cough for a trial. This is an observational study (a study drug is not being tested) to measure the burden of cough in patients with pulmonary fibrosis. The study involves the use of digital technology (Strados Remote Electronic Stethoscope) to measure cough.

ClinicalTrials.gov ID: NCT05670587

Sites are located throughout the US. Please contact +1 (833) 602-2368 or unitedstates@bitrialsupport.com.